Drug
Lyl797
Lyl797: highest development phase Phase 1, developed by Lyell Immunopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Lyell Immunopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| LYL797 NCT05274451 | Phase 1 | Triple Negative Breast Cancer |
Latest
No recent events.
Follow Lyl797 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.